DGAP-News

amp biosimilars AG successfully out-licenses first biosimilar - Seite 2

represents a great step forward - with others soon to follow."

This out-licensing of its first biosimilar also marks amp biosimilar's
successful market launch in China. In the course of this, the company
benefits from the intensive work and the extensive network that was set up
in recent years. The Chinese pharmaceutical market is currently the second
largest in the world and has been growing in the past by up to 25 percent
per year. By 2020 the pharmaceutical market is expected to have a volume of
1 trillion US dollars. The Chinese biosimilar market may actually be the
largest in the world by 2017, surpassing Europe.

About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand
on global therapeutic markets and is one of the most innovative and dynamic
biosimilar companies in Europe. The company is headquartered in Hamburg and
run by a team of leading industry experts. The development of a wide
variety of biosimilars will provide patients around the world with access
to life-improving and life-saving therapies. The combination of a research
platform with state-of-the-art analytics, process technology and clinical
expertise as well as regulatory know-how, makes amp biosimilars AG one of
the leading companies for biosimilar development and marketing. Thanks to
an international network of leading pharmaceutical companies, amp
biosimilars AG also has direct access to the strongest growing markets in
the world. With this approach amp biosimilars AG has a key position in one
of the fastest growing life science markets in the near future. amp
biosimilars AG has been listed on the Munich Stock Exchange since April 1,
2015. For more information please go to www.ampbiosimilars.com.

Contact:
MC Services AG
Fabian Lorenz
T [phone]
Email: [e-mail]



---------------------------------------------------------------------

28.05.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


362361 28.05.2015